US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab
The US Food and Drug Administration's advisory panel has voted to keep a black box warning on US pharma major Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline).
The committee said that the warning of reports of suicide and depression should remain on the box. Some 11 members voted in favor, six members said the label should be changed and one voted to remove it. Pfizer had previously asked the US FDA to remove the warning, saying that there is no risk of increased psychiatric problems with the drug.
Benefits of Novartis’ secukinumab outweigh the risks
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze